RxDoctor Payments DataLook up a doctor →

Bassem Rouphael, MD

Internal Medicine · Minneapolis, MNNPI 1851520381

Payments from drug & device makers

$10,384in general payments, 2019–2025

Across 347 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Bard Peripheral Vascular, Inc.$2K
  • AstraZeneca$733
  • OPKO Pharmaceuticals, LLC$587
  • Mallinckrodt Hospital Products Inc.$538
  • Amgen$506
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$3,14030%
  • Food & beverage$7,11769%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,384 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$294,434
Medicare patients
538
Services billed
5,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol169$119,421
RayaldeeCalcifediol42$52,744
AuryxiaFerric Citrate20$46,257
KerendiaFinerenone45$38,760
LokelmaSodium Zirconium Cyclosilicate33$25,536
VeltassaPatiromer Calcium Sorbitex15$14,202
Sevelamer Carbonate54$8,809
Febuxostat23$3,575
Ethacrynic Acid11$2,278
Calcitriol143$2,040
Allopurinol96$1,791
Calcium Acetate14$1,602
Cinacalcet Hcl18$1,481
Bumetanide49$1,280
Losartan Potassium197$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$733$144,957202 claims
OPKO Pharmaceuticals, LLCRayaldee$587$52,74442 claims
Akebia Therapeutics IncAuryxia$345$46,25720 claims
BayerKerendia$430$38,76045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →